Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180331 · ClinicalTrials.gov registry record · NA
Feasibility, Acceptability, and Preliminary Efficacy of a Novel Personalized Mobile Intervention for Suicide - Open Trial
A NA study of Suicide and Suicidal Ideation, sponsored by Butler Hospital.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05180331: Completed NA study of Suicide and Suicidal Ideation, sponsored by Butler Hospital.
NCT05180331 is a NA study of Suicide and Suicidal Ideation that has completed, run by Butler Hospital. The registered enrollment target is 10 participants, below the 6,990-participant average among 92 other Suicide trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05180331, a NA study of Suicide and Suicidal Ideation, has completed, sponsored by Butler Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this grant is to conduct pilot testing on a novel personalized mobile intervention for suicide - Mobile Application to Prevent Suicide (MAPS) - and to establish feasibility, acceptability, safety, and primary outcomes (i.e., suicidal ideation and behavior; re-hospitalization).
Primary Outcome
Measured by recruitment rate.
Conditions Studied
Interventions
- BEHAVIORAL Mobile Application to Prevent Suicide (MAPS)
Study Locations (1)
Rhode Island
- Butler Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2024-05-20 |
| Phase | NA |
What the finished NCT05180331 record still lists
NCT05180331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 6,990-participant average among 92 other Suicide trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Suicide appearing as the primary indexed condition, and to 1 intervention - of which Mobile Application to Prevent Suicide (MAPS) is the first listed.
NCT05180331 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT05180331 about?
NCT05180331 is a clinical study titled "Feasibility, Acceptability, and Preliminary Efficacy of a Novel Personalized Mobile Intervention for Suicide - Open Trial". The primary aim of this grant is to conduct pilot testing on a novel personalized mobile intervention for suicide - Mobile Application to Prevent Suicide (MAPS) - and to establish feasibility, acceptability, safety, and primary outcomes (i.e., suicidal ideation and behavior; re-hospitalization).
What is the current status of trial NCT05180331?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2023-12-14. Estimated completion is 2024-05-20.
What conditions does trial NCT05180331 study?
This clinical trial studies the following conditions: Suicide, Suicidal Ideation, Suicide, Attempted, Suicide and Self-harm.
What interventions are being tested in trial NCT05180331?
The interventions under investigation include: Mobile Application to Prevent Suicide (MAPS) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05180331?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05180331 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Suicide
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05180331's enrollment target sits among peer trials
10 92nd of 92 the lowest of 92 other Suicide trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Suicide trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Randomized Clinical Trial of Supplementing Brief Psychotherapy With a Mobile App
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Real-time Examination of Skills and Coping Use in Teen's Everyday Lives
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI